Neuralstem shares soar as FDA OKs first ALS stem cell trial

The FDA has cleared the way for Neuralstem to begin the first human trial of a stem cell therapy for Lou Gehrig's disease, and the news lit a fire under its stock that fueled a 57 percent hike in its share price.

Researchers will recruit 12 patients with Amyotrophic Lateral Sclerosis, a fatal disease with no therapy approved to treat it. Each of the patients will get up to 10 injections of the developer's neural stem cells in the spine. The company is out to determine if the treatment is safe and can slow down the degenerative process that leads to paralysis and death.

"In work with animals, these spinal cord stem cells both protected at-risk motor neurons and made connections to the neurons controlling muscles," says Dr. Eva L. Feldman, a principal investigator. "We don't want to raise expectations unduly, but we believe these stem cells could produce similar results in patients with ALS."

- check out the press release
- read the story from the Washington Business Journal

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.